Next Generation TIL: OBX-115 Engineered TIL Cell Therapy with Regulatable mbIL15
Time: 9:30 am
day: Day 1
Details:
• OBX-115 is an engineered TIL cell therapy that leverages regulatable membrane-bound IL15 (mbIL15) to improve the expansion, persistence, safety, and efficacy of TIL cell therapy for patients with solid tumors
• Unlike IL2, mbIL15 promotes a predominant CD8+, memory, and “stem-like” progenitor phenotype, and does not increase immunosuppressive regulatory T-cells
• Clinically, we have observed a safety profile that is positively differentiated from nonengineered TIL cell therapy, which requires high-dose systemic IL2, as well as promising early efficacy and translational correlates
